Research and Markets: Research and Forecast of China Antifreeze Market, 2014-2018
Business Wire - Tue Feb 25, 6:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/wq7dvj/research_and) has announced the addition of the "Research and Forecast of China Antifreeze Market, 2014-2018" report to their offering.
Ironwood Pharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 3:00PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2014 Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 3:30 p.m. Eastern Time at The Boston Marriott Copley Place.
Use Options For A Chance To Buy IRWD At A 16% Discount
at The Street - Fri Feb 14, 11:10AM CST
Looking back to 3 days ago, Ironwood Pharmaceuticals priced a 13,725,500 share secondary stock offering at $12.75 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the...
Ironwood Pharmaceuticals Inc reports exercise of 2.059 Class A common stock in underwriters' option in public offering
M2 - Fri Feb 14, 3:27AM CST
Medicines company Ironwood Pharmaceuticals Inc (NasdaqGS:IRWD) said on Thursday that the underwriters of its public offering of Class A common stock have exercised their option to purchase an additional 2,058,825 shares, at a public offering price of USD12.75 per share.
Ironwood Pharmaceuticals Announces Exercise of Underwriters' Option in Public Offering of Common Stock
Business Wire - Thu Feb 13, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the underwriters of its previously announced public offering of Class A common stock have exercised their option to purchase an additional 2,058,825 shares at a public offering price of $12.75 per share. As a result, Ironwood will issue a total of 15,784,325 shares in the offering and will receive aggregate net proceeds, after underwriting discounts and commissions and other estimated offering expenses, of approximately $190.4 million. The offering is expected to close on February 14, 2014, subject to the satisfaction of customary closing conditions.
4 Stocks Breaking Out on Big Volume
at The Street - Thu Feb 13, 5:00AM CST
These stocks trading on unusual volume are within range of triggering breakout trades.
Ironwood Pharmaceuticals Appoints Julie McHugh to Board of Directors
Business Wire - Wed Feb 12, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today the appointment of Julie McHugh to its board of directors. Ms. McHugh has served in leadership positions for both large pharmaceutical and small biotechnology businesses and brings to the Ironwood board significant experience in operations, strategy, product development and marketing.
Ironwood Pharmaceuticals Prices Public Offering of Common Stock
Business Wire - Tue Feb 11, 10:22PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced the pricing of an underwritten public offering of 13,725,500 shares of its Class A common stock at a price of $12.75 per share to the public. All of the shares are being offered by Ironwood. The gross proceeds to Ironwood from this offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Ironwood. The offering is expected to close on February 14, 2014, subject to the satisfaction of customary closing conditions.
Does Furiex Pharmaceuticals Inc Still Have Upside Potential?
George Budwell, The Motley Fool - Motley Fool - Mon Feb 10, 5:30PM CST
Little known Furiex Pharmaceuticals caught investors napping last week after reporting strong top-line results from two late-stage studies for its experimental irritable bowel syndrome with diarrhea, or IBS-d, drug eluxadoline. Specifically,...
Ironwood Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire - Mon Feb 10, 3:04PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that it has commenced a $150 million underwritten public offering of its Class A common stock. All of the shares are being offered by Ironwood. Ironwood will grant the underwriters a 30-day option to purchase additional shares equal to up to 15% of the number of shares of Class A common stock sold in the offering.
Ironwood Receives Notice of Allowance for Methods of Use Formulation Patent Expected to Extend LINZESS(R) Patent Protection Through 2031
Business Wire - Mon Feb 10, 7:00AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of using LINZESS(R) (linaclotide) to treat patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The patent application, co-owned by Ironwood and Forest Laboratories, Inc., is expected to issue in mid-2014 and extend LINZESS patent protection into 2031.
Ironwood Pharmaceuticals to Present at Leerink Global Healthcare Conference
Business Wire - Fri Feb 07, 3:00PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 2014 Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 1:50 p.m. Eastern Time at the Waldorf Astoria Hotel in New York.
Biotech Stock Mailbag: Furiex, La Jolla Pharma, Sarepta
at The Street - Fri Feb 07, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Furiex Pharma Diarrhea Drug Produces Solid Results in Pivotal Studies
at The Street - Tue Feb 04, 8:55AM CST
An FDA approval filing for Furiex's eluxadoline will be submitted in the second quarter.
How Ironwood (IRWD) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 7:48AM CST
Ironwood is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
Narrower-than-Expected Loss at Ironwood, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 22, 2:31PM CST
Ironwood Pharmaceuticals reported a loss of 43 cents per share in the fourth quarter of 2013.
Wall Street Has Taken A Sharp Turn Into Forest Laboratories, Inc.
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jan 21, 4:32PM CST
Institutional investors and sell-side analysts are rather infamous for gnat-like attention spans and the capacity to dramatically change their opinions in relatively short periods of time. So, too, has it been with Forest Labs , though it certainly...
Why Ironwood Pharmaceuticals Shares Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Jan 21, 3:43PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ironwood Pharmaceuticals , a...
Ironwood Pharmaceuticals Provides Fourth Quarter 2013 Investor Update
Business Wire - Tue Jan 21, 6:10AM CST
--- $118.8 million LINZESS net product sales in first full year of launch; $138.0 million LINZESS net product sales since December 2012 launch -
Insider Trading Alert - IRWD, GMED, DST, RRC And GTN Traded By Insiders
at The Street - Fri Jan 17, 9:30AM CST
Stocks with insider trader activity include IRWD, GMED, DST, RRC and GTN
Ironwood Pharmaceuticals (IRWD) Stock Research Links